https://www.globenewswire.com/news-release/2018/05/17/1508005/0/en/BeiGene-Initiates-Phase-3-Trial-of-Pamiparib-as-Maintenance-Therapy-in-Chinese-Patients-with-Ovarian-Cancer.html
BEIJING, China and CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused...
beigeneinitiatesphasetrialpamiparib